Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 8 · below the Ichimoku cloud · RSI 24 (oversold) · MACD above its signal
None of the 29 investors followed here reported a position in VXL.V in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a VXL.V trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for VXL.V.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.4 | 0.0 | 7.1 | 86.7 | -17.9 | -21.7 | -2.8 | 0.0 | -17.1 | 0.0 | +0.0% | ||
| 2025 | 0.0 | 0.0 | 0.0 | 0.0 | 2200.0 | -13.0 | 7.5 | -25.6 | 15.6 | -2.7 | -22.2 | 3.6 | +1350.0% |
| 2024 | 0.0 | 0.0 | -40.0 | 0.0 | -33.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −60.0% |
| 2023 | -25.0 | 66.7 | -20.0 | 0.0 | -25.0 | 33.3 | -25.0 | 0.0 | 0.0 | -33.3 | 0.0 | 150.0 | +25.0% |
| 2022 | -13.3 | -15.4 | -18.2 | -22.2 | -14.3 | 0.0 | 16.7 | -14.3 | 0.0 | -16.7 | -40.0 | 33.3 | −73.3% |
| 2021 | 40.0 | -63.1 | -19.4 | -4.0 | -20.8 | -10.5 | 0.0 | -17.6 | 100.0 | -35.7 | -5.6 | -11.8 | −75.0% |
| 2020 | -14.3 | 333.3 | 38.5 | -30.6 | -20.0 | -20.0 | 25.0 | 0.0 | 30.0 | -3.8 | -32.0 | 252.9 | +757.1% |
| 2019 | 50.0 | 0.0 | 0.0 | -22.2 | 0.0 | 28.6 | -22.2 | 14.3 | -12.5 | 14.3 | 0.0 | -12.5 | +16.7% |
| 2018 | 69.2 | 13.6 | 20.0 | -16.7 | -48.0 | 7.7 | 7.1 | 20.0 | 0.0 | -55.6 | -25.0 | 0.0 | −53.8% |
| 2017 | 5.0 | -4.8 | -5.0 | 15.8 | 9.1 | 16.7 | -32.1 | 0.0 | -15.8 | -25.0 | -16.7 | 30.0 | −35.0% |
| 2016 | 0.0 | 0.0 | 165.0 | -13.2 | -17.4 | -18.4 | -9.7 | -7.1 | 7.7 | 3.6 | -20.7 | -13.0 | +0.0% |
| 2015 | -38.5 | 0.0 | -12.5 | 14.3 | 25.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −23.1% |
| 2014 | 66.7 | -40.0 | 0.0 | 0.0 | 33.3 | 25.0 | -40.0 | 100.0 | -66.7 | -35.7 | -22.2 | 85.7 | −38.1% |
| 2013 | -14.3 | -33.3 | 0.0 | -25.0 | 0.0 | 33.3 | 25.0 | 20.0 | 0.0 | -33.3 | 0.0 | -25.0 | −57.1% |
| 2012 | 0.0 | 0.0 | -14.3 | 0.0 | 33.3 | -37.5 | 0.0 | -40.0 | 66.7 | -20.0 | 25.0 | -30.0 | −50.0% |
| 2011 | 50.0 | 0.0 | 41.7 | -11.8 | -20.0 | -16.7 | -10.0 | 22.2 | -27.3 | -25.0 | 16.7 | 0.0 | −12.5% |
| 2010 | -30.0 | -14.3 | 66.7 | -40.0 | 0.0 | 0.0 | 0.0 | 16.7 | 14.3 | −20.0% |
No analyst coverage for this instrument.
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company is headquartered in Toronto, Canada.
No recent headlines.